Clinical Trials Browser

Neuroendocrine Tumors

Carcinoma, Renal Cell

Thyroid cancer, Hurthle cell

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Recurrence, Endometrial Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Breast Neoplasms

Brain Neoplasms, Glioblastoma, Glioma

Neuroendocrine Tumors

Uterine Neoplasms, Endometrial Neoplasms

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

Mastocytosis, Systemic

Neoplasm Metastasis, Pancreatic Neoplasms

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Prostatic Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Cutaneous Squamous Cell Carcinoma

Carcinoma, Renal Cell

Breast Neoplasms

Autistic Disorder, Hamartoma Syndrome, Multiple, Intellectual Disability

Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

Neoplasms, Peutz-Jeghers Syndrome, Polyps

Advanced, Persistent, or Recurrent Endometrial Cancer

Breast Neoplasms, Ovarian Neoplasms

Familial ependymoma, Ependymoma

Triple Negative Breast Neoplasms

Breast Neoplasms

Neurofibroma, Neurofibromatosis 1

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Breast Neoplasms

Carcinoma, Renal Cell

Advanced Malignant Solid Neoplasm

Breast Neoplasms

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Breast Neoplasms

Neoplasm Metastasis

Fibrolamellar hepatocellular carcinoma

Astrocytoma, Oligodendroglioma

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Glioma, Brain Stem Neoplasms

Carcinoma, Renal Cell

Clinical Trials

COMPETE

CLEAR

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

e3

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

AMEERA-1

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

S0931

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

SEQTOR

RAD001 in Recurrent Endometrial Cancer Patients

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

CONTRAC

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

MIST

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

EVACEL

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Everolimus for Children With Recurrent or Progressive Ependymoma

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

BOLERO-5

DCLNF1

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

BOLERO-4

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

ENTRATA